YE-NEO-001

YE-NEO-001 is a personalized cancer vaccine composed of heat-killed yeast genetically modified to express patient-specific neoantigen epitopes. It is designed as an immunotherapy to stimulate the immune system, particularly T-cell responses, against tumor cells by presenting unique tumor-derived antigens specific to each patient. The vaccine is developed by NantBioScience and has been investigated primarily for use in patients with solid tumors who have completed potentially curative therapy and are under surveillance for recurrence. The approach leverages molecular profiling of both tumor and normal DNA to identify neoepitopes, which are then used to create a customized therapeutic vaccine[1][2][3][4][5][6][7][8].

Other names

Personalized neoepitope yeast vaccine